Eribulin in Cancer Treatment

Marine Drugs

Umang Swami¹  Umang Shah²  Sanjay Goel² 

[1] University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA; E-Mail:;Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USA; E-Mail:

关键词: breast cancer;    EMBRACE;    eribulin;    E7389;    Halichondrin B;    Halaven™;    microtubule inhibitor;    NSC 707389;   

DOI  :  10.3390/md13085016

来源: mdpi

【 摘 要 】

Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.